Success Stories

August 17th, 2009

Set Up A New Subsidiary

In December 2008, Anhui Biochem United Pharmaceutical Co., Ltd was permitted to prepare for establishing a subsidiary: Anhui Biochem Medical Sales Co., Ltd.
In March 2009, Anhui Biochem Medical Sales Co., Ltd was inspected and approved by Anhui Food & Drug Administration.

Acquires One Bio-pharmaceutical Company in Hefei

In April 2008, the company invested RMB 130.7million (USD 19 million) to acquire a bio-pharmaceutical company located at Hi-Tech Development Zone in Hefei, to set up a subsidiary Anhui Biochem (Bio-Pharma) Co., Ltd for RD and manufacture of

Anhui Biochem United Pharmaceutical Co., Ltd Welcome You!

August 17th, 2009

Anhui Biochem United Pharmaceutical Co., Ltd. is one of the leading pharmaceutical manufacturing enterprises in China specializing in the development of high quality Anti-HIV/AIDS intermediates, active pharmaceutical ingredients (APIs) and finished pharmaceutical products (FPPs). The company has rapidly integrated scientific research, development and production specializing in the field of synthetic technology of chiral compounds. The mission of the company is to develop high-quality products with updated science and technology innovation to help save lives.

Company highlights include:

1. Approval by Health Canada for lamivudine API.
2. Active partnerships with multinational pharmaceutical companies.
3. China SFDA grants GMP approval for Lafutidine API with GMP certificate (No.: 皖J0253).
4. China SFDA grants GMP approval for Lamivudine API with GMP certificate (No.:皖K0276).
5.China SFDA grants GMP approval for Anhui Biochem (Bio-Pharma) Co., Ltd.
6.USD 10 million capital investment from UK investment fund.

Investments & Acquisitions:
1. In June 2007, the company received a USD 10 million investment by QVT Fund LP (UK).
2. In September 2007, the company invested RMB 160 million (USD 23 million) to expand its API manufacturing base.
3. In April 2008, the company invested RMB 130.7million (USD 19 million) to acquire a bio-pharmaceutical company located at Hi-Tech Development Zone in Hefei, to set up a subsidiary – Anhui Biochem (Bio-Pharma) Co., Ltd – for R&D and manufacture of the finished pharmaceutical products (FPPs) for hepatitis B and HIV/AIDS.
4. In December 2008, Anhui Biochem United Pharmaceutical Co., Ltd was permitted to prepare for establishing a subsidiary: Anhui Biochem Medical Sales Co., Ltd.
5. In March 2009, Anhui Biochem Medical Sales Co., Ltd was inspected and approved by Anhui Food & Drug Administration.
6. The total registered capital of the company is RMB 510 million (USD 75 million).

The total site area of the company is 205,128m2(308 acres), including the API manufacturing site of 110,556 m2 (166 acres), the FPPs manufacturing site of 77,256 m2(116 acres) and the R&D base of 17,316 m2 (26 acres).

The company has established a well-equipped R&D team with 5 Doctors and 12 Masters, they are working under the direction of the senior engineers who are honored by the State Council subsidy. The company is controlled by the total quality management system, and also persists in the idea of green environment protection through use of modern facilities and utilities for treatment of the waste liquid and gas.